Can a blood test or Mini-Tumor predict immunotherapy success in lung cancer?
NCT ID NCT06405230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether special lab tools—like analyzing tiny particles from blood cells or growing mini-tumors in a dish—can predict how well immunotherapy drugs work in people whose lung cancer has returned. About 40 participants will receive standard immunotherapy drugs (pembrolizumab or dostarlimab) along with chemotherapy. The goal is to see if changes in these lab tests match what is seen on special PET scans, which could help doctors personalize treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab and dostarlimab (immunotherapy drugs)
What this could lead to
If successful, this could lead to better ways to predict which lung cancer patients will benefit from immunotherapy, making treatment more personalized.
What could go wrong
This is a small, early-phase study focused on testing new measurement tools, not on proving the drugs work. The tools may not reliably predict outcomes in larger, more diverse groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NON-SMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGLondon, SE1 9RT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••